• ERT and Bioclinica are now Clario. Find out more about our new name, and why we have come together.

Your using an unsupported browser. Please update to a modern browser for a better experience.

Cardiac safety is the #1 reason for drug development failure & post-market recalls.

High-quality data and reporting are essential to drive decisions in both site-based and DCTs from Phase 1 to Phase IV. As the most trusted name in cardiac safety with 50 years of experience, Clario centralizes the approach to data collection with rigorous, responsive and reliable tools that deliver credible, compliant, high-quality data you can be certain of.

Our goal is always to:

  • Improve patient safety and enrollment
  • Increase data access leading to reduced timelines 
  • Deliver scientific-grade data to reduce variability
  • Solutions with the patients in mind

Regardless of therapeutic area or where your data is coming from, Clario helps you collect reliable evidence with certainty—in site-based and DCT environments— enabling you to bring new drugs and therapies to market. Learn how our solutions and scientific experts can help you effectively pitch, expertly design and efficiently implement successful cardiac safety data for your submission.

Clario advances your decentralized clinical trial with the extensible power of certainty

Global capabilities

With Clario-operated logistics hubs in the US, EU and Japan with the largest, most diverse inventory of validated equipment and 136,000 devices shipped per year.

Clinical and scientific expertise

50 years of clinical trial experience in cardiac safety plus a team of cardiologists who bring more than 200 years of clinical expertise powers certainty.

The broadest endpoint technology platform

Our flexible equipment and overread services ensure consistent, quality data, so you can be certain you’re collecting credible data.

Patient-centric experiences

We help power trial continuity patient reminders, coaching and demonstrations to ensure patients experience success.

Proven results earn trust

13,887

Trials supported

580

New drug approvals

50

Years science

600+

QT studies

200+

Combined years of clinical experience

480+

Unique programs

87+

Approvals from TQTS alone

230+

Sponsors

Cardiac Safety Science Team

Robert Kleiman headshot

Robert Kleiman, MD

VP & Chief Medical Officer, Cardiology

Borje Darpo headshot

Borje Darpo, MD, PhD

Chief Scientific Officer, Cardiac Safety

Jeff Morganroth headshot

Joel Morganroth, MD

Chief Scientific Advisor, Cardiac Safety

Mori Krantz headshot

Mori J. Krantz, MD, FACP, FACC

Senior Cardiologist & Chief Science Advisor Cardiac Safety and Cardiovascular Imaging

Peem Lorvidhaya, MD

Senior Director, Cardiology

Bruce Lloyd headshot

Bruce Lloyd, MD

Medical Director

Onglee Weng headshot

Onglee Weng, MBA, MD

Vice President, General Manager, Clario Shanghai

Jean T Barbey headshot

Jean T. Barbey, MD

Expert Cardiac Safety Medical Advisor

Jeff Heilbraun headshot

Jeff Heilbraun, MS

Vice President, Medical and Scientific Affairs, Cardiology

Luc Dekie headshot

Luc Dekie, PhD

Director Scientific Affairs, Cardiology

Increase confidence in site performance with Clario Certified Sites.

Clario Certified Sites have completed our Certified Site program to ensure that each study is conducted in an optimal manner and results in the highest quality data. The certification program requires each site to go through an extensive training and testing process. These sites help sponsors reduce study start-up time with well-trained and well-equipped sites.

Learn more or speak with one of our experts

Our team of clinical trial cardiac safety experts are always available to address questions about our cardiac safety solutions. Submit your contact information and we’ll be in touch shortly.